Bristol Meyers-Squibb Lung Cancer CA209-816-00

Randomized, OpenLabel, Phase 3 Trial of Nivolumab Plus Ipilimumab or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Early Stage NSCLC

The purpose of this study is to determine the safety and effectiveness of nivolumab plus ipilimumab or nivolumab plus chemotherapy compared to chemotherapy alone in the treatment of Early Stage Non-Small Cell Lung. This study has multiple primary endpoints. The first primary completion date of Pathological Complete Response is anticipated to be reached September 2020. The completion date for all primary outcome measures is expected May 2023.

Eligibility Criteria:

1. Early stage IB-IIIA, operable non-small cell lung cancer, confirmed in tissue.
2. Lung function capacity capable of tolerating the proposed lung surgery.
3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.
4. Available tissue of primary lung tumor.

This study is for patients age 18 and older.

Available at: Hospital of Central Connecticut